



Tea Consumption and Risk of Bladder Cancer: A Dose-Response Meta-Analysis

Hong Weng^{1,2†}, Xian-Tao Zeng^{1,2†}, Sheng Li^{1,2}, Joey S. W. Kwong³, Tong-Zu Liu² and Xing-Huan Wang^{1,2*}

¹ Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China, ² Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China, ³ Chinese Evidence-Based Medicine Center and Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu, China

Background and Objective: Controversial results of the association between tea (black tea, green tea, mate, and oolong tea) consumption and risk of bladder cancer were reported among epidemiological studies. Thus, we performed a meta-analysis of observational studies to investigate the association.

OPEN ACCESS

Edited by:

Brian James Morris, University of Sydney, Australia

Reviewed by:

Qihan Dong, University of Sydney, Australia Jie Liu, Fourth Military Medical University, China

*Correspondence:

Xing-Huan Wang wangxinghuan1965@163.com; wangxinghuan@whu.edu.cn

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Integrative Physiology, a section of the journal Frontiers in Physiology

Received: 03 November 2016 Accepted: 29 December 2016 Published: 23 January 2017

Citation:

Weng H, Zeng X-T, Li S, Kwong JSW, Liu T-Z and Wang X-H (2017) Tea Consumption and Risk of Bladder Cancer: A Dose-Response Meta-Analysis. Front. Physiol. 7:693. doi: 10.3389/fphys.2016.00693 **Methods:** We searched the PubMed and Embase for studies of tea consumption and bladder cancer that were published in any language up to March, 2016. Cohort or case-control studies were included in the meta-analysis. All statistical analyses were performed in Stata 12.0 software. Odds ratios (ORs) and 95% confidence intervals (Cls) were calculated to assess the relationship between tea consumption and risk of bladder cancer.

Results: Totally, 25 case-control studies (15 643 cases and 30 795 controls) and seven prospective cohort studies (1807 cases and 443 076 participants) were included. The meta-analysis showed that tea consumption was not significantly associated with bladder cancer risk (OR = 0.96, 95% Cl 0.86–1.06) (in a comparison of highest vs. lowest category). No non-linearity association was observed between tea consumption and bladder cancer risk (P = 0.51 for non-linearity). Specific analysis for black tea, green tea, and mate yielded similar results. The dose-response analysis showed the summary OR for an increment of 1 cup/day of tea consumption was 1.01 (95% Cl 0.97–1.05).

Conclusion: Results based on current meta-analysis indicated that no significant association was observed between tea consumption and risk of bladder cancer.

Keywords: bladder cancer, dose-response, risk factor, tea consumption, meta-analysis

INTRODUCTION

Bladder cancer is a very common disease worldwide, accounting for \sim 429 800 new cases and 165 100 deaths occurred in 2012 worldwide (Torre et al., 2015). Although bladder cancer incidence rates have been declining in most Western countries over the past decades, it remains an important and deadly cancer in the United States (Siegel et al., 2015). Bladder cancer incidence rates have been stable or declining over the past decades, and it may be owing to reductions in smoking prevalence, increasing the intake of fruits and vegetables, and schistosomiasis control and treatment (Chavan et al., 2014; Xu et al., 2015). However, feasible measures for the prevention of bladder cancer are

1

still a miss. Therefore, more risk factors of bladder cancer should be identified for the prevention of bladder cancer.

Tea is a commonly consumed beverage worldwide. Previous research in vitro and in vivo has indicated that tea polyphenols present protective effects against some cancers including bladder cancer (Conde et al., 2014). Although the relationship between tea consumption and risk of bladder cancer is biologically plausible (Lu et al., 1999; Sagara et al., 2010), epidemiological studies on this theme have obtained inconsistent results. Two meta-analyses of observation studies concluded that tea consumption was not associated with an elevated risk of bladder cancer (Zeegers et al., 2001b; Qin et al., 2012). Nevertheless, a recently published meta-analysis suggested that tea consumption was associated with decreased risk of bladder cancer in Western countries (Zhang et al., 2015). In addition, one meta-analysis indicated that green tea reduced bladder cancer risk in Asians (Wang X. et al., 2013), and the other one suggested that high level of tea consumption in smokers was related to an elevated risk of bladder cancer and high level of black tea intake in females was related to a reduced risk of bladder cancer (Wu et al., 2013). Therefore, the relationship between tea intake and the risk of bladder cancer remains controversy. Additionally, none of above published meta-analyses performed a dose-response analysis. In order to clarify the relationship between tea consumption and the risk of bladder cancer, we performed the present dose-response meta-analysis of all published observational studies.

METHODS

Eligible Criteria

This study was conducted and reported following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement (Moher et al., 2009). The inclusion criteria were as following: (1) case-control study or cohort study; (2) exposure was tea (including green tea, black tea, mate, and oolong tea) consumption; (3) outcome was incidence of bladder cancer; (4) study provided the odds ratios (ORs) or relative risks (RRs) with corresponding 95% confidence intervals (CIs) or data necessary to calculate them. When multiple papers reported on the same study were identified, the most informative or complete article would be included.

Search Strategy

PubMed and Embase were searched for studies examining the relationship between tea consumption and bladder cancer that were published in any language up to March, 2016. Search items including "tea," "drink," "beverage," or "fluid" combined with "bladder cancer," "bladder neoplasm," "bladder tumor," "bladder carcinoma," "urothelium carcinoma," or "transitional cell carcinoma" had been allied in the database retrieve. We also scanned the reference lists from all retrieved papers to identify additional studies. No restriction was applied.

Data Extraction

All data were extracted independently and crosschecked by two reviewers according to the pre-specified inclusion criteria. Discrepancy was resolved by discussion. The following information were extracted: First author, publication year, country, study period, sex, study design, type of control subjects for case-control studies, sample size, type of tea, consumption categories, the OR or RR with 95% CI for each category (the results adjusted with most potential confounders), and adjusted variables. Crude ORs or RRs with 95% CIs were only extracted when no adjusted ORs or RRs were presented. In addition, ORs or RRs with 95% CIs in different smoking status were also extracted for assessing the effect of smoking, which is an important confounding factor for bladder cancer.

Methodological Quality Assessment

We performed methodological quality assessment of the included studies using the Newcastle-Ottawa Scale (Stang, 2010; Zeng X. et al., 2015), which is a nine-star scale contained three main items: Selection (0–4 stars), comparability (0–2 stars), and exposure (for cohort study, 0–3 stars), or outcome (for case-control study, 0–3 stars).

Statistical Analysis

The statistical analysis for the overall relationship between tea consumption and bladder cancer risk were based on randomeffects model and on comparisons of the highest vs. lowest category of tea consumption (Zeng X. T. et al., 2015). The measure of interest is the OR with corresponding 95% CI. For studies reported the information by subsets (sex, smoking status, type of tea), we summarized the ORs with 95% CIs of the subsets in a fixed-effect model before aggregating them into overall analysis.

For dose-response analysis, we used the G-L method (Greenland, 1987; Orsini et al., 2012) to explore the relationship between tea consumption and bladder cancer risk. The potential non-linearity association was examined by modeling tea intake using restricted cubic splines with three knots at 10, 50, and 95% of the distribution. We assigned the median or middle point of the upper and lower boundaries in each category as the corresponding dose to the related OR for each study. If the highest category is open-ended, we assumed the both boundaries to be the same as the closest category. The lowest boundary was assumed to be zero if it was not present. Studies only reported three levels or more were included in the dose-response analysis.

The Cochran Q and I^2 statistics were applied to detect statistical heterogeneity among studies (Higgins and Thompson, 2002). Heterogeneity was confirmed with a P-value of less than 0.1 or I^2 value of more than 50%. To explore the potential heterogeneity among studies, stratified analyses were performed according to study design, sex, study location, smoking status, adjustment for age, and adjustment for smoking. In addition, subgroup analysis of type of tea had been carried out to further investigate the association between different type of tea consumption and the risk of bladder cancer. The metaregression analysis was conducted to detect the between-group heterogeneity based on the aforementioned variables. Sensitivity analysis was performed by removing the studies that only provided crude ORs to examine the influence of these studies on the summarized Ors (Leng et al., 2015). Publication bias was detected by funnel plot and Egger's regression method (Egger

et al., 1997). All statistical analysis was performed with Stata 12.0 (StataCorp, College Station, TX). All statistical tests were two-sided, with P < 0.05 considered statistically significant.

RESULTS

Study Characteristics

Detailed literature selection process was presented in **Figure 1**. A total of seven prospective cohort studies (Heilbrun et al., 1986; Chyou et al., 1993; Michaud et al., 1999; Nagano et al., 2000; Zeegers et al., 2001a; Kurahashi et al., 2009; Ros et al., 2011) included 443 076 participants, in which 1807 developed

bladder cancer, and 25 case-control studies (Morgan and Jain, 1974; Howe et al., 1980; Hartge et al., 1983; Ohno et al., 1985; Jensen et al., 1986; Risch et al., 1988; Slattery et al., 1988; Clavel and Cordier, 1991; Nomura et al., 1991; D'Avanzo et al., 1992; Kunze et al., 1992; La Vecchia et al., 1992; Wilkens et al., 1996; Bruemmer et al., 1997; Lu et al., 1999; Bianchi et al., 2000; Geoffroy-Perez and Cordier, 2001; Woolcott et al., 2002; Wakai et al., 2004; Bates et al., 2007; De Stefani et al., 2007; Demirel et al., 2008; Jiang et al., 2008; Hemelt et al., 2010; Wang J. et al., 2013) including 15 643 cases and 30 795 controls, published from 1974 through 2013, were identified in the meta-analysis. Characteristics of included studies were presented in Table 1. Of



Study	Sex	Design	Study period	Country	Cases/controls, n	Type of tea and consumption categories	OR/RR (95% CI)	Adjustments	NOS
Morgan and Jain, 1974	Both	HCC	NR	Canada	232/232	Tea, cups/day (men)		None	4
						0	1.00		
						0.1–0.9	0.38 (0.10–1.43)		
						1.0-2.9	0.72 (0.24–2.14)		
						3.0-4.9	1.24 (0.35–4.41)		
						≥5	0.45 (0.13-1.62)		
						Tea, cups/day (women)			
						0	1.00		
						0.1-0.9	0.54 (0.25–1.17)		
						1.0-2.9	0.49 (0.26–0.94)		
						3.0-4.9	1.04 (0.51-2.13)		
						≥5	1.52 (0.65–3.53)		
Howe et al., 1980	Both	PCC	1974–1976	Canada	632/632	Tea (men)		None	5
						Never	1.0		
						Ever	1.0 (0.7–1.4)		
						Tea (women)			
						Never	1.0		
						Ever	0.5 (0.2–1.0)		
Hartge et al., 1983	Both	PCC	1977–1978	US	2982/5782	Tea, cups/wk		Age, race,	6
						(men)	1.0	geographic area tobacco	
						0	1.0	and coffee	
						7 1 14	1.1 (0.6-1.4)		
						7.1-14	1.1 (0.7 - 1.3)		
						>14 Tea, cups/wk	1.0 (0.7–1.4)		
						(women)			
						0	1.0		
						0.1–7	1.1 (0.7–1.7)		
						7.1–14	1.7 (1.0–2.9)		
						>14	1.2 (0.7–2.0)		
Ohno et al., 1985	Both	PCC	1976–1978	Japan	292/589	Black tea (men)	1.00	Age and smoking	7
						NUL	1.00	onnorang	
						Black tea	0.95 (0.06-1.52)		
						Not	1.00		
						Ever	0.55 (0.29–1.03)		
Jensen et al., 1986	Both	PCC	1979–1981	Denmark	371/771	Tea, cups/day (men)		Smoking	6
						0	1.0		
						<2	0.8 (0.6-1.2)		
						2–4	2.1 (1.3–3.4)		
						4–6	1.5 (0.7–3.2)		
						Tea, cups/day (women)	· · · /		
						0	1.0		

TABLE 1 | Characteristics of studies of tea consumption and bladder cancer risk.

-2 0.8 (0.4-1.5) -4 1.4 (0.6-3.0) Hellbrun et sl., 1998 M Cehort 1985–1985 US 57/7833 Back tea (men) Age and anching 8 Hellbrun et sl., 1998 M Cehort 1985–1985 US 57/7833 Back tea (men) Age and anching 9 Risch et al., 1988 Both POC 1379–1982 Carada 876/1688 Regmp oilly 1.0 1.00 Age, and anching 8 Risch et al., 1988 Both POC 1379–1982 Carada 876/1688 Regmp oilly 1.00 Age, sec, diabates and Unstructure Interviewing 1.00 Age, sec, diabates and Unstructure Interusture Interviewing	Study	Sex	Design	Study period	Country	Cases/controls, n	Type of tea and consumption categories	OR/RR (95% CI)	Adjustments	NOS
2-4 14.0.0-3.0 (4-8 10.0.4-2.5) Heltbrun et al., 1988 M Oxhort 1985-1985 LS (Lagarnese anneaby) 57/7833 Bisk-tes in-mont -twicawk 1.0 (1.0.0.632-2.0) Age and ambring 8 Rich et al., 1988 Both PCC 1970-1982 Canda 826/1668 Tes (men) Average daily tragarroy (2039) 1.00 (0.0.8, 0.78-1.20) Life time comunication disbetter 8 Sillettery et al., 1988 Both PCC 1977-1982 LIS 419/869 Tes, 6-corce serving/wk Age, sex, disbetter and before and infectors Age, sex, disbetter and infectors 8 Sillettery et al., 1988 Both PCC 1977-1982 LIS 419/869 Tes, 6-corce serving/wk Age, sex, disbetter and infectors Age, nex, disbetter and infectors Age, nex, disbetter infectors Age, nex, disbetter infect							<2	0.8 (0.4–1.5)		
4-6 1.0 (0.4-2.9) Heitbrun et al., 1998 M Ochort 1465-1985 US 57/7833 Almost never - values/Wk 1.0 Age and embeding 8 Bisch et al., 1988 Bisch PCO 1979-1982 Ganada 876/1688 Test (mer) Nat Average daily (Keay) 1.00 Age and embeding 8 Statuy et al., 1988 Bisch PCO 1977-1982 US 419/889 Test (mer) Nat Average daily (Keay) 1.00 Age and embeding 8 Statuy et al., 1988 Bisch PCO 1977-1982 US 419/889 Test (mer) Nat Average daily (Keay) 0.98 (0.76-1.22) (Keay) Age, acc avering/Wk Age, acc avering/Wk <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>2–4</td><td>1.4 (0.6–3.0)</td><td></td><td></td></t<>							2–4	1.4 (0.6–3.0)		
Helibun at al., 1998 M Cohort 1965-1985 US (Japanese anoshy) 57/7833 Black isa (men) - kNoa(Wk 14 (0,77-2,84) Age and encking Age and encking Age and encking B Risch et al., 1988 Both PCC 1979-1982 Canada 876/1688 Tag (men) Not encypercy (2030y) 1.00 Aerrage daily requency (2030y) 1.00 Aerrage daily requency (2030y) 1.00 Aerrage daily requency (2030y) 1.00 Aerrage daily requency (2030y) 1.00 Aerrage daily requency (2030y) 1.00 Aerrage daily requency (2030y) Both PCC 1977-1982 US 419/889 Tag, Boundo escription/ 3 dubetes Age, exc, dabetes and blacks and							4–6	1.0 (0.4–2.5)		
(Japanese anosity) Amost never : -Wice Wk 0.8 (0.33-1.04) Mont never : -Wice Wk 0.8 (0.33-1.04) amoking : -Wice Wk 0.8 (0.33-1.04) Risch et al., 1988 Both PCC 1979-1982 Canada 876/1668 Reg (men) Net : -Wice Wk 0.8 (0.33-1.04) 1.00 1.04 (0.90-1.20) aduates UIt imme cigaretite consumption and heatry of diabetes 8 ////////////////////////////////////	Heilbrun et al., 1986	М	Cohort	1965–1985	US	57/7833	Black tea (men)		Age and	8
amounty -thickewik 1.0(77-2-54) 2-4 (inewikk) 1.0(77-2-54) 2-4 (inewikk) 1.0(77-2-54) 2-6 (inexistic) Riach et al., 1988 Both PCC 1970-1982 Canada 576/1688 Tag (mon) Not Average daily (3/day) 1.00 Jagarette consumption architectory of dabutes 3 agreente consumption architectory of dabutes 8 adverage (3/day) Sistery et al., 1988 Both PCC 1977-1982 US 419/889 Tea, 8-conce source (3/day) Age, sex, dabutes 8 dabutes 8 dabutes Sistery et al., 1988 Both PCC 1977-1982 US 419/889 Tea, 8-conce source (3/day) Age, sex, dabutes 8 dabutes 8 dabutes Sistery et al., 1988 Both PCC 1977-1982 US 419/889 Tea, 8-conce source (3/day) Age, sex, dabutes 8 dabutes 4 dabutes 8 dabutes Cower and Cordier, 1991 Both PCC 1977-1982 US 419/889 Tea, 8-conce source (3/day) 1.00 1.00 1.00 Cower and Cordier, 1991 Both HCC 1984-1987 France 690/680 Tea, copo/day					(Japanese		Almost never	1.0	smoking	
Plach et al., 1988 Both PCC 1979-1982 Canada 876/1668 Tae (ner) Not 1.00 Aeroga daly (K/dy) 1.00 1.04 (J.99-1.20) Life time digentite and history of dabutes 8 Slattery et al., 1988 Both PCC 1977-1982 US 419/889 Tee (norm) Not 1.00 0.05 (0.78-1.22) Age, sex, dabutes 8 Slattery et al., 1988 Both PCC 1977-1982 US 419/889 Tee, formotice aeroings/motice are ingenote constraints Age, sex, dabutes and package 8 Slattery et al., 1988 Both PCC 1977-1982 US 419/889 Tee, formotice aeroings/motice aeroings/motice are ingenote constraints Age, sex, dabutes and package 8 Clavel and Conder, 1991 Both PCC 1977-1982 US 419/889 Tee, capa/day (Ever smoked) 1.00 1.30					ancestry)		<twice td="" wk<=""><td>1.4 (0.77–2.54)</td><td></td><td></td></twice>	1.4 (0.77–2.54)		
Sonociday 0.8 (0.33-1.9) Risch et al., 1988 Both PCC 1979-1982 Canada 876/1668 Ties (nen) Not (3/day) 1.00 Life time cigaretic incouncy (3/day) 5.00 1.00 Sono-1.20 Sono-amption and history of dabetes 8 Slattery et al., 1998 Both PCC 1977-1982 US 419/889 Ties, 6-ounce servings/wk (Never anokad) 0.00 App. sex. dabates and bidder infections 8 Slattery et al., 1998 Both PCC 1977-1982 US 419/889 Ties, 6-ounce servings/wk (Ever anokad) 0.00 1.00 4dabates and bidder infections 8 Clavel and Corclier, 1991 Both PCC 1977-1982 US 419/889 Ties, 6-ounce servings/wk (Ever anokad) 0.00 1.00							2–4 times/wk	1.0 (0.38–2.60)		
Pach et al., 1988 Both PCC 1970–1982 Canada 876/1688 Text (man) Text (man) (3/day) Life time (abelies) Bit (abelies) Life time (abelies) Bit (abelies) Life time (abelies) Bit (abelies) Life time (abelies) Bit (abelies) PCC 1970–1982 US 419/889 Text, (amon) (abelies) Life time (abelies) Bit (abelies) Age, sex, (abelies) Age, sex, (abelies) Age, sex, (abelies) Age, sex, (abelies) Bit (abelies) Age, sex, (abelies) Bit (abelies) Age, sex, (abelies) Bit (abelies) Bit (abelies) Bit (abelies) Age, sex, (abelies) Bit (abelies) Bit (abelies) Bit (abelies) Age, sex, (abelies) Bit (abelies) Bit (abelies) <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>>once/day</td><td>0.8 (0.33–1.94)</td><td></td><td></td></t<>							>once/day	0.8 (0.33–1.94)		
Average day (\$/day) 1.04 (0.30-1.20) (\$/day) consumption abstrop of abstrop abstrop (\$/day) consumption abstrop (\$/day) consumption abstrop (\$/day) consumption abstrop (\$/day) Statery et al., 1988 Boh PCC 1977-1982 US 419/889 Tas, 8-ounce san/ings/Wk Age, sax, diabetes and biodure 8 Statery et al., 1988 Boh PCC 1977-1982 US 419/889 Tas, 8-ounce san/ings/Wk Age, sax, diabetes and biodure 8 Clavel and Cordier, 1991 Boh PCC 1977-1982 US 419/889 Tas, 8-ounce san/ings/Wk 1.00 10.09-3.68) infections 1 Clavel and Cordier, 1991 Boh HCC 1984-1987 France 690/690 Tes, cups/day (rem, current smokers) 1 0.00 1 and residence and residence 6 1991 Log 1.00 1.00 1 2.73 (0.86-8.67) >1 1 4.04 (0.28-7.62) >1 4.04 (0.28-7.62) >1 Age, hospital and residence 6 1991 Line Line 1.00 1.00 1 0.6 1 1.00 1	Risch et al., 1988	Both	PCC	1979–1982	Canada	876/1668	Tea (men) Not	1.00	Life time cigarette	8
Tea (women) Not 1.00 Not 1.00 Not 0.98 (0.78-1.22) trequency (2/dsay) 0.98 (0.78-1.22) trequency (2/dsay) Slattery et al., 1988 Both PCC 1977-1982 US 419/889 Tea, 8-ounce treatings/Wk (Never smoken) Age, sex, diabetes and biadder 8 Slattery et al., 1988 Both PCC 1977-1982 US 419/889 Tea, 8-ounce servings/Wk (Never smoken) Age, sex, diabetes and biadder 8 Level and Cordier, 1991 Both PCC 1977-1982 US 419/889 Tea, 8-ounce servings/Wk (Never smoken) 1.00 1 1.00 Clavel and Cordier, 1991 Both HCC 1984-1987 France 690/690 Tea, cups/day (men, Non-smokers) Age, hospital and residence 6 1991 Leve processor 1.00 1.00 1 2.73 (0.86-6.67) >1 1.04 (0.05-4.126) 1991 Leve processor Leve processor 1.00 1.00 1 2.73 (0.86-6.67) 1 1991 Leve processor 1.00 1.00 1.00 1.00 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Average daily frequency (3/day)</td> <td>1.04 (0.90–1.20)</td> <td>consumption and history of diabetes</td> <td></td>							Average daily frequency (3/day)	1.04 (0.90–1.20)	consumption and history of diabetes	
Not 1.00 Average daily (2/day) 0.98 (0.78-1.22) (2/day) Age, sox, diabetes and bladder infections 8 Stattery et al., 1988 Both PCC 1977-1982 US 419/889 Tea, 8-ounce servings/Wk (Never smoked) Age, sox, 1.00 8 8 Verser smoked) 0 tea 1.00 1.00 1-3 cups tea 1.91 (0.99-3.68) 2.4 cups tea 1.00 1 7 6 7							Tea (women)			
Average daily frequency 0.98 (0.78-1.22) (Mequay) Age, sex, dabetes and bladder 8 Slattery et al., 1988 Both POC 1977-1982 US 419/889 Tea, 8-ounce servings/Wk (Never annoked) Age, sex, dabetes and bladder 8 Slattery et al., 1988 Both POC 1977-1982 US 419/889 Tea, 8-ounce servings/Wk (Ever annoked) Age, sex, dabetes and bladder 8 Clavel and Cordler, 1991 Both HCC 1984–1987 France 690/690 Tea, cuprofday (men, Non-smokers) Age, hospital and residence 6 1991 Liss HCC 1984–1987 France 690/690 Tea, cuprofday (men, Non-smokers) Age, hospital and residence 6 1991 Liss Liss Liss Liss Age, hospital and residence 6 100 1 2.73 (0.86-6.67) =1 1.00 1 3.81 (0.83-6.69) =1 1.46 (0.28-7.62) 101 1.68 (0.28-2.60) =1 1.00 1.00 1 1.04 (0.31-3.59)							Not	1.00		
Slattery et al., 1988 Both PCC 1977-1982 US 419/889 Tea, 8-ounce servings/vk (Never smoked) Age, sex, diabetes and bladder 8 diabetes and bladder 9 diabetes and bladder 9 di							Average daily frequency (3/day)	0.98 (0.78–1.22)		
0 tea 1.00 infections 1-3 cups tea 1.91 (0.99-3.68) 24 cups tea 2.25 (1.29-3.91) 24 cups tea 2.25 (1.29-3.91) 34 cups tea 0.02 (0.54-1.25) 24 cups tea 0.82 (0.54-1.25) 24 cups tea 0.82 (0.54-1.25) 24 cups tea 0.82 (0.55-1.29) 24 cups tea 0.82 (0.55-1.29) Clavel and Cordier, Both HCC 1984–1987 France 690/690 Tea, cups/day (men, Nor-smokers) Age, hospital 6 and residence 1 2.73 (0.86-8.67) >1 0 1.00 1 2.73 (0.86-8.67) >1 >1 0.48 (0.05-1.60) Tea, cups/day (men, Nor-smokers) 1.00 1 3.81 (0.83-6.69) >1 1 3.81 (0.83-6.69) >1 1.46 (0.28-7.62) Tea, cups/day (moren, Nor-smokers) 1.00 1 0 1.00 1 0 1.00 1 0.85 (0.28-2.60) >1 1.04 (0.31-3.59)	Slattery et al., 1988	Both	PCC	1977–1982	US	419/889	Tea, 8-ounce servings/wk (Never smoked)		Age, sex, diabetes and bladder	8
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $						0 tea	1.00	infections		
Participation 2.25 (1.29-3.91) Tea, 8-ounce ServingsWk (Ever smoked) 0 tea 0 tea 1.00 1-3 cups tea 0.82 (0.54-1.25) 24 cups tea 0.84 (0.55-1.29) Clevel and Cordier, Both HCC 1984–1987 France 690/690 Tea, cups/day (men, Non-smokers) Age, hospital 6 1991 0 1.00 1 2.73 (0.86-8.67) 1 1 0.48 (0.05-4.60) Tea, cups/day (men, current smokers) 1.00 1 3.81 (0.83-6.69) 21 1.46 (0.28-7.62) Tea, cups/day (women, Non-smokers) 1 1.46 (0.28-7.62) 1 0.45 (0.28-2.60) 1 1.00 1 0.85 (0.28-2.60) 21 0.45 (0.28-2.60) 1 0.40 (0.31-3.59) 1						1-3 cups tea 1.91 (0.99-3.68)				
Tea, 8-ounce servings/MK (Ever smoked) Tea, 8-ounce servings/MK (Ever smoked) I.00 I.00 I.3 cups tea 0.82 (0.54–1.25) I.24 cups tea 0.84 (0.55–1.29) I.24 cups tea 0.84 (0.55–1.29) I.24 cups tea 0.84 (0.55–1.29) I.24 cups tea I.26 cups/day Age, hospital 6 1991 Both HCC 1984–1987 France 690/690 Tea, cups/day Men, Non-smokers) I.00 1 2.73 (0.86–8.67) I.20 I.20 I I.48 (0.05–4.60) I I.20 I I.20 I I.20 I I.20 I I.20 I I.20 I <							\geq 4 cups tea	2.25 (1.29–3.91)		
O tea 1.00 1-3 cups tea 0.82 (0.54-1.25) ≥4 cups tea 0.84 (0.55-1.29) Clavel and Cordier, Both HCC 1984-1987 France 690/690 Tea, cups/day (men, Non-smokers) Age, hospital and residence 6 0 1.00 1 2.73 (0.86-8.67) 1.00 1 2.73 (0.86-8.67) 1.00 1 2.73 (0.86-8.67) >1 0.48 (0.05-4.60) 1 3.81 (0.83-6.69) 0 1.00 1 3.81 (0.83-6.69) 1 1.46 (0.28-7.62) 1 1.46 (0.28-7.62) Tea, cups/day (women, Non-smokers) 0 1.00 0 1.00 1 0.85 (0.28-2.60) 1 1 0.48 (0.03-4.60) 1 1.04 (0.31-3.59)							Tea, 8-ounce servings/wk (Ever smoked)			
1-3 cups tea 0.82 (0.54-1.25) ≥4 cups tea 0.84 (0.55-1.29) Clavel and Cordier, Both HCC 1984–1987 France 690/690 Tea, cups/day (men, Non-smokers)) Age, hospital and residence 6 and residence 1991 0 1.00 1 2.73 (0.86–8.67) >1 0.48 (0.05–4.60) Tea, cups/day (men, current smokers) 0 1.00 1 3.81 (0.83–6.69) >1 0.48 (0.05–4.60) Tea, cups/day (men, current smokers) 0 1.00 1 3.81 (0.83–6.69) >1 1.46 (0.28–7.62) Tea, cups/day (men, Non-smokers) 0 1.00 1 0.85 (0.28–2.60) 1.00 1 0.85 (0.28–2.60) >1 1.04 (0.31–3.59)							0 tea	1.00		
≥4 cups tea 0.84 (0.55-1.29) Clavel and Cordier, Both HCC 1984-1987 France 690/690 Tea, cups/day (men, Non-smokers) Age, hospital 6 and residence 6 1991 0 1.00 1 2.73 (0.86-8.67) >1 0.48 (0.05-4.60) Tea, cups/day (men, current smokers) 0 1.00 1 3.81 (0.83-6.69) >1 1.46 (0.28-7.62) Tea, cups/day (women, Non-smokers) 0 1.00 1 0.85 (0.28-2.60) >1 0.85 (0.28-2.60) >1 >1 1.04 (0.31-3.59) 1.04 (0.31-3.59) 0 1.00							1–3 cups tea	0.82 (0.54–1.25)		
Clavel and Cordier, 1991 Both HCC 1984–1987 France 690/690 Tea, cups/day (men, Non-smokers) Age, hospital and residence 6 0 1.00 1 2.73 (0.86–8.67) >1 0.48 (0.05–4.60) 1 2.73 (0.86–8.67) >1 0.48 (0.05–4.60) 1 2.73 (0.88–6.67) >1 0.48 (0.05–4.60) 1 2.73 (0.88–6.67) >1 0.48 (0.05–4.60) 1 3.81 (0.83–6.69) >1 1.00 1 3.81 (0.83–6.69) >1 1.46 (0.28–7.62) 1 1.46 (0.28–7.62) 1 1.46 (0.28–7.62) 1 1.40 (0.21–7.62) 1 1.00 1 0.85 (0.28–2.60) >1 1 0.85 (0.28–2.60) >1 1 0.48 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1.04 (0.31–3.59) 1 1 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>≥4 cups tea</td> <td>0.84 (0.55–1.29)</td> <td></td> <td></td>							≥4 cups tea	0.84 (0.55–1.29)		
0 1.00 1 2.73 (0.86–8.67) >1 0.48 (0.05–4.60) Tea, cups/day (men, current smokers) Tea, cups/day 0 1.00 1 3.81 (0.83–6.69) >1 1.46 (0.28–7.62) Tea, cups/day (women, Non-smokers) Tea, cups/day 0 1.00 1 0.85 (0.28–2.60) >1 1.04 (0.31–3.59)	Clavel and Cordier, 1991	Both	HCC	1984–1987	France	690/690	Tea, cups/day (men, Non-smokers)		Age, hospital and residence	6
1 2.73 (0.86–8.67) >1 0.48 (0.05–4.60) Tea, cups/day (men, current smokers) 0 1.00 1 3.81 (0.83–6.69) >1 1.06 (0.28–7.62) Tea, cups/day (women, Non-smokers) 0 1.00 1 0.85 (0.28–2.60) >1 0.4 (0.31–3.59)							0	1.00		
 >1 0.48 (0.05-4.60) Fea, cups/day (men, current smokers) 0 1.00 3.81 (0.83-6.69) >1 1.46 (0.28-7.62) Tea, cups/day (women, Non-smokers) 0 1.00 1.00 1.00 1.00 1.00 1.04 (0.31-3.59) 							1	2 73 (0 86_8 67)		
Tea, cups/day (men, current smokers) 0 1.00 1 3.81 (0.83–6.69) >1 1.46 (0.28–7.62) Tea, cups/day (women, Non-smokers) 0 1.00 1 0.85 (0.28–2.60) >1 1.04 (0.31–3.59)							∼1	2.73 (0.00-0.07)		
(men, current smokers) 0 1.00 1 3.81 (0.83–6.69) > 1 1.46 (0.28–7.62) Tea, cups/day (wornen, Non-smokers) 0 1.00 1 0.85 (0.28–2.60) > 1 1.04 (0.31–3.59)							Tea cups/day	0.40 (0.00-4.00)		
0 1.00 1 3.81 (0.83–6.69) >1 1.46 (0.28–7.62) Tea, cups/day (women, Non-smokers) 0 1.00 1 0.85 (0.28–2.60) >1 1.04 (0.31–3.59)							(men, current smokers)			
1 3.81 (0.83–6.69) >1 1.46 (0.28–7.62) Tea, cups/day (women, Non-smokers) 0 1.00 1 0.85 (0.28–2.60) >1 1.04 (0.31–3.59)							0	1.00		
>1 1.46 (0.28–7.62) Tea, cups/day (women, Non-smokers) 0 1.00 1 0.85 (0.28–2.60) >1 1.04 (0.31–3.59)							1	3.81 (0.83–6.69)		
Tea, cups/day (women, Non-smokers) 1.00 0 1.00 1 0.85 (0.28–2.60) >1 1.04 (0.31–3.59)							>1	1.46 (0.28–7.62)		
0 1.00 1 0.85 (0.28–2.60) >1 1.04 (0.31–3.59)							Tea, cups/day (women, Non-smokers)			
1 0.85 (0.28–2.60) >1 1.04 (0.31–3.59)							0	1,00		
>1 1.04 (0.31–3.59)							1	0.85 (0.28-2.60)		
							>1	1.04 (0.31–3.59)		

Study	Sex	Design	Study period	Country	Cases/controls, n	Type of tea and consumption categories	OR/RR (95% CI)	Adjustments	NOS
						Tea, cups/day (women, current smokers)			
						0	1.00		
						>0	0.19 (0.04–0.84)		
Nomura et al., 1991	Both	PCC	1977–1986	US (Caucasian	261/522	Tea, cup-years (men)		Smoking	8
				and		Non-drinkers	1.0		
				Japanese)		Drinkers	0.8 (0.5–1.4)		
						1–30	0.9 (0.5–1.5)		
						≥31	0.7 (0.4–1.3)		
						Tea, cup-years (women)			
						Non-drinkers	1.0		
						Drinkers	0.6 (0.2-1.5)		
						1–30	0.6 (0.2–1.6)		
						≥31	0.5 (0.2–1.8)		
						Black tea, cup-years (men)			
						Non-drinkers	1.0		
						Drinkers	1.0 (0.7–1.5)		
						1–10	1.2 (0.8–1.8)		
						≥11	0.7 (0.4–1.2)		
						Black tea, cup-years			
						(women)			
						Non-drinkers	1.0		
						Drinkers	0.6 (0.3-1.3)		
						1-10	0.6 (0.2-1.3)		
						211	0.7 (0.3–1.7)		
D'Avanzo et al., 1992	Both	HCC	1985–1990	Italy	555/855	Tea		Age, sex, education, smoking,	7
						Non drinkora	1.0	alcohol, and	
						Drinkers	0.9 (0.6-1.2)	exposure to	
						Dilikers	0.9 (0.0-1.2)	occupation	
Kunze et al., 1992	Both	HCC	1977–1985	Germany	620/675	Black tea, cups/day (men)		Smoking	6
						0	1.0		
						1–2	1.1 (0.8–1.4)	-1.4)	
						3–4	1.4 (0.8–2.2)		
						≥5	1.4 (0.7–3.1)		
						Black tea, cups/day			
							1.0		
						1.2			
						3_4	0.7 (0.3 - 1.4) 0.7 (0.3 - 1.9)		
						>5	0.7 (0.3 - 1.0) 0.7 (0.2 - 2.2)		
						<u> </u>	0.7 (0.2-2.3)		

Study	Sex	Design	Study period	Country	Cases/controls, n	Type of tea and consumption categories	OR/RR (95% CI)	Adjustments	NOS
La Vecchia et al.,	Both	HCC	1983–1990	Italy	365/6147	Теа		Age, sex, area	6
1992						Non-users	1.0	education,	
						Users (≥1	0.8 (0.5-1.1)	smoking, and	
						cup/day)		coffee	
Chyou et al., 1993	Both	Cohort	1965–1985	US	96/7995	Green tea		Age and	8
				(Japanese ancestry)		Almost never	1.00	smoking	
				anocou yy		Ever	1.34 (0.79–2.27)		
						Black tea			
						Almost never	1.00		
						Ever	1.32 (0.87–2.00)		
Wilkens et al., 1996	Both	PCC	1979–1986	US	271/522	Tea (men)		Age, smoking,	8
				(Caucasian		Q1 (low)	1.0	occupation,	
				Japanese)		Q2	0.8 (0.5–1.4)	of dark green	
						Q3	1.0 (0.6–1.7)	vegetables in	
						Q4 (high)	0.7 (0.4–1.3)	men, and total	
						Tea (women)		vitamin C	
						Q1 (low)	1.0	consumption	
						Q2	0.6 (0.2–1.4)	III WOITIEIT	
						Q3	0.7 (0.3–1.8)		
						Q4 (high)	0.9 (0.4–2.2)		
						Green tea (men)			
						Q1 (low)	1.0		
						Q2	1.1 (0.6–1.9)		
						Q3 (high)	1.1 (0.6–2.3)		
						Green tea (women)			
						Q1 (low)	1.0		
						02	0.8 (0.3-2.1)		
						Q3 (high)	0.9 (0.3-2.6)		
	Dette	D 00	1007 1000		000/405	T	0.0 (0.0 2.0)	A	0
1997	Both	PCC	1987-1990	05	202/405	day, wk, or mo		and smoking	0
						(men)			
						≤1/mo	1.0		
						>1/mo-1/wk	0.6 (0.3–1.2)		
						>1/WK-//WK	0.9 (0.5–1.6)		
						>//WK	2.5 (1.2–5.3)		
						lea, cups per day, wk, or mo (women)			
							1.0		
						$\geq 1/mo$ 1/w/c	0.2 (0.1.1.1)		
						<1/w/2-7/w/2	0.0(0.1-1.1) 0.8(0.2-1.2)		
						>7/wk	0.9 (0.4–2.1)		
Lu et al., 1999	Both	HCC	1996–1997	China	40/160	Теа		Age, sex. date	8
,				(Taiwan)		Non-drinkers	1.00	of admission,	-
						≤1/day	4.30 (0.51–35.88)	family history,	
						>1/day	2.77 (1.11–6.92)	ethnicity, and	
						-	. ,	SITIOKING	

Study	Sex	Design	Study period	Country	Cases/controls, n	Type of tea and consumption categories	OR/RR (95% CI)	Adjustments	NOS
						Non-drinkers	1.00		
						Drinkers	3.00 (1.20-7.47)		
Michaud et al., 1999	Both	Cohort	1986–1996	US	252/47909	Tea (1 cup)		Geographic region, age,	6
						<1/mo	1.0	smoking,	
						1/mo-4/wk	0.98 (0.74–1.29)	and intake of	
						5/wk–1/day	0.74 (0.49–1.11)	fruits and	
						≥2/day	0.69 (0.40–1.19)	vegetables	
Bianchi et al., 2000	Both	PCC	1986–1989	US	1452/2434	Tea, cups/day		Age, sex, education, smoking, family history, occupation,	7
						None	1.0	beverage,	
						<1	0.9 (0.7–1.1)	chlorinated	
						1–2.6	1.1 (0.9–1.3)	vegetable,and	
						>2.6	0.9 (0.7–1.1)	coffee	
Nagano et al., 2000	Both	Cohort	1979–1981	Japan	114/38540	Green tea		Age, gender,	6
						0–1/day	1.00	radiation dose,	
						2–4/day	1.07 (0.61–2.00)	education	
						≥5/day	1.07 (0.58–2.08)	BMI, and	
						Black tea	4.00	calendar time	
						0/wk	1.00		
						1/WK	0.79 (0.45–1.33)		
						≥2/WK	0.81 (0.43–1.44)		
Geoffroy-Perez and Cordier, 2001	Both	HCC	1984–1987	France	765/765	Tea, ml/wk (men) 0	1.00	Age, center, residence, and	6
						1–950	1.42 (0.90–2.22)	smoking	
						>950	1.17 (0.72–1.90)		
						Tea, ml/wk (women)			
						0	1.00		
						1–950	0.91 (0.39-2.13)		
						>950	1.08 (0.50–2.32)		
Zeegers et al.,	Both	Cohort	1986–1992	Netherland	569/3123	Tea, cups/day		Age, sex,	6
2001a						0	1.00	smoking,	
						<2	0.64 (0.45–0.89)	coffee	
						2->3	0.71 (0.53–0.93)		
						3-<4	0.51 (0.37–0.72)		
						4-<5	0.46 (0.34–0.64)		
						≥5	0.53 (0.39–0.74)		
Woolcott et al., 2002	Both	PCC	1992–1994	Canada	927/2118	Tea, cups/day		Age, sex,	7
						<1	1.00	education,	
						1–2	1.18 (0.97–1.43)	enerav.	
						3-4	1.15 (0.89–1.49)	calcium, fiber,	
						20	1.31 (0.92–1.87)	and beer	

Study	Sex	Design	Study period	Country	Cases/controls, n	Type of tea and consumption categories	OR/RR (95% CI)	Adjustments	NOS
Wakai et al., 2004	Both	HCC	1994–2000	Japan	124/744	Green tea, cups/day <1 1–4 5–9 ≥10 Black tea, cups/day Almost never Occasionally ≥1	1.00 1.40 (0.74–2.62) 2.67 (1.44–4.94) 1.18 (0.49–2.84) 1.00 0.96 (0.60–1.53) 0.16 (0.02–1.14)	Age, sex, year of first visit, and cigarettes	6
Bates et al., 2007	Both	PCC	1996–2000	Argentina	114/114	Mate con bombilla, L/day (ever-smoker) ≤0.09 >0.09–0.36 >0.36–0.9 >0.9 Mate cocido, L/day (ever-smoker) 0 >0–<0.25 ≥0.25	1.00 1.36 (0.36–5.08) 1.41 (0.57–3.46) 1.16 (0.46–2.93) 1.00 3.60 (0.31–41.3) 1.30 (0.65–2.60)	Age, sex, residence, education, cigarettes, and an indicator variable for whether or not the other type of mate was consumed at that time	6
De Stefani et al., 2007	Both	НСС	1996–2000	Uruguay	255/501	Tea, cups/day Never drinkers <1 ≥1 Mate, L/day Never drinkers 0.1–0.9 1.0–1.9 ≥2.0	1.0 2.1 (1.4–3.1) 4.1 (1.7–9.9) 1.0 1.3 (0.6–2.7) 2.1 (1.2–3.9) 3.7 (1.9–7.1)	Sex, age, residence, urban/rural status, education, family history, BMI, occupation, smoking, coffee, soft, and milk	6
Demirel et al., 2008	Both	HCC	2001–2006	Turkey	164/324	Black tea	0.74 (0.38–1.43)	None	5
Jiang et al., 2008	Both	PCC	1987–1999	US	1586/1586	Tea, cups/day 0 <1 1–2 3–4 ≥5	1.00 0.96 (0.74–1.26) 0.95 (0.76–1.20) 1.16 (0.80–1.69) 0.88 (0.54–1.45)	Education, carotenoids, number of years as a hairdresser/barber, and smoking	5
Kurahashi et al., 2009	Both	Cohort	1990–2005	Japan	206/104440	Green tea, cups/day (men) <1 1-2 3-4 ≥5 Green tea, cups/day (women)	1.0 1.18 (0.73–1.91) 0.71 (0.43–1.18) 0.90 (0.56–1.45)	Age, area, smoking, alcohol, and coffee	8

Study	Sex	Design	Study period	Country	Cases/controls,	Type of tea and consumption categories	OR/RR (95% CI)	Adjustments	NOS
						<3	1.0		
						3–4	1.22 (0.49–3.00)		
						≥5	2.29 (1.06–4.92)		
Hemelt et al., 2010	Both	HCC	2005–2008	China	381/371	Green tea, cups/day		Age, sex, smoking	7
						No	1.00		
						<daily< td=""><td>0.83 (0.54–1.27)</td><td></td><td></td></daily<>	0.83 (0.54–1.27)		
						Daily	1.02 (0.71–1.48)		
						<4	1.23 (0.76–1.97)		
						≥4	0.83 (0.53–1.28)		
						Black tea, cups/day			
						No	1.00		
						<daily< td=""><td>0.82 (0.56-1.22)</td><td></td><td></td></daily<>	0.82 (0.56-1.22)		
						Daily	0.86 (0.59–1.25)		
						<4	0.82 (0.49–1.37)		
						≥4	0.88 (0.57–1.38)		
Ros et al., 2011	Both	Cohort	1992–2000	European countries	513/233236	Tea, ml/day <12 for men; <16 for women	1.00	Age, sex, center, smoking, and	8
						12–199 for men; 16–263 for women	1.09 (0.78–1.52)	energy intake from fat and Non-fat	
						≥200 for men; ≥264 for women	0.91 (0.64–1.30)	sources	
Wang J. et al., 2013	Both	HCC	1999–2007	US	1007/1299	Tea, cups/day Never	1.00	Age, sex, ethnicity,	7
						0.1-0.70	0.74 (0.59–0.92)	energy intake,	
						≥0.71	0.65 (0.53–0.81)	and smoking	
						Black tea, cups/day	. ,		
						Never	1.00		
						0.1-0.56	0.71 (0.57–0.88)		
						≥0.57	0.67 (0.54–0.83)		
						Green tea, cups/day			
						Never	1.00		
						0.1-0.13	0.82 (0.61–1.11)		
						≥0.14	0.60 (0.45–0.79)		

BMI, body mass index; HCC, hospital-based case-control; PCC, population-based case-control; NR, not report; OR, odds ratio; RR, relative risk; CI, confidence interval; NOS, Newcastle-Ottawa Scale.

the 32 studies, seven were cohort studies, 12 were hospital-based case-control studies, and 13 were population-based case-control studies. Of these studies, 11 conducted in US (Hartge et al., 1983; Heilbrun et al., 1986; Slattery et al., 1988; Nomura et al., 1991; Chyou et al., 1993; Wilkens et al., 1996; Bruemmer et al., 1997; Michaud et al., 1999; Bianchi et al., 2000; Jiang et al., 2008; Wang J. et al., 2013), **9 in Europe** (Jensen et al., 1986; Clavel and Cordier, 1991; D'Avanzo et al., 1992; Kunze et al., 1992; La Vecchia et al.,

1992; Geoffroy-Perez and Cordier, 2001; Zeegers et al., 2001a; Demirel et al., 2008; Ros et al., 2011), **4 in Canada** (Morgan and Jain, 1974; Howe et al., 1980; Risch et al., 1988; Woolcott et al., 2002), **4 in Japan** (Ohno et al., 1985; Nagano et al., 2000; Wakai et al., 2004; Kurahashi et al., 2009), two in China (Lu et al., 1999; Hemelt et al., 2010), one in Argentina (Bates et al., 2007) and one in Uruguay (De Stefani et al., 2007). The estimated quality of all included studies was in the rage of 4–8 stars.

Tea Consumption and Bladder Cancer

The meta-analysis of all 32 studies, no significant association was observed between high tea consumption and risk of bladder cancer (highest vs. lowest: OR = 0.96, 95% CI 0.86–1.06) (**Figure 2**), with moderate to high heterogeneity ($I^2 = 54.2\%$, $P_{\text{heterogeneity}}$). For cohort studies, the pooled OR was 0.88 (95% CI 0.67–1.17), with certain between-study heterogeneity ($I^2 = 67.8\%$, $P_{\text{heterogeneity}} = 0.005$) (**Table 2**). For hospital-based case-control studies, the pooled OR was 0.98 (95% CI 0.78–1.24), with certain evidence of between-study heterogeneity ($I^2 = 63.2\%$, $P_{\text{heterogeneity}}$). For population-based case-control studies, the pooled OR was 1.00 (95% CI 0.91–1.10), with no evidence of between-study heterogeneity).

Four cohort studies (Michaud et al., 1999; Nagano et al., 2000; Zeegers et al., 2001a; Kurahashi et al., 2009) and 12 case-control studies (Morgan and Jain, 1974; Hartge et al., 1983; Jensen et al., 1986; Clavel and Cordier, 1991; Kunze et al., 1992; Lu et al., 1999; Bianchi et al., 2000; Woolcott et al., 2002; Wakai et al., 2004; Jiang et al., 2008; Hemelt et al., 2010; Wang J. et al., 2013) were included for the dose-response meta-analysis of tea consumption. The results had been shown in **Figure 3**. There was no evidence of a non-linearity association between tea consumption and bladder cancer risk ($P_{non-linearity} = 0.51$). Thus, a linear regression model was applied. The summary OR of bladder cancer for an increase of one cup of tea per day was 1.01 (95% CI 0.97–1.05, $P_{linear} = 0.73$). For cohort

Study ID		OR (95% CI)	% Weight
HCC	1		
Morgan et al, 1974 -		1.04 (0.52, 2.09)	1.68
Clavel et al, 1991		0.66 (0.30, 1.44)	1.41
D'Avanzo et al, 1992		0.90 (0.64, 1.27)	3.95
Kunze et al, 1992	_	1.34 (0.71, 2.52)	1.94
La Vecchia et al, 1992		0.80 (0.54, 1.19)	3.49
Lu et al, 1999		2.77 (1.11, 6.92)	1.08
Geoffroy-Perez et al, 2001		1.14 (0.76, 1.71)	3.37
VVakai et al, 2004		0.86 (0.38, 1.93)	1.32
De Stefani et al. 2007	-	4.10 (1.70, 9.89)	1.15
Hemelt et al. 2000		0.74(0.36, 1.44)	1.01
Mong et al. 2012		0.65 (0.62, 1.10)	4.34 E AC
Subtotal (Leguared = 62.2% = 0.002)			0.40 21.00
Subtotal (I-squared = 65.2%, p = 0.002)	\rightarrow	0.90 (0.70, 1.24)	31.00
PCC		0.00 (0.66 4.24)	1 21
Hortee et al. 1983		1.06 (0.05, 1.24)	4.24
Ohno et al. 1985		0.84 (0.63, 1.42)	4.50
loncon et al. 1986		1 27 (0 71 2 28)	2.18
Risch et al. 1988		1.02 (0.91, 2.20)	6.50
Slattery et al. 1988		1 21 (0 86, 1 70)	4 01
Nomura et al 1991		0.65 (0.39, 1.09)	2.58
Wilkens et al. 1996 -		0.76 (0.47, 1.23)	2.80
Bruemmer et al. 1997	-	1.59 (0.91, 2.77)	2.33
Bianchi et al, 2000		0.90 (0.72, 1.13)	5.30
Woolcott et al. 2002		1.31 (0.92, 1.87)	3.87
Bates et al, 2007		1.16 (0.46, 2.93)	1.06
Jiang et al, 2008		0.88 (0.54, 1.44)	2.71
Subtotal (I-squared = 14.0%, p = 0.304)	•	1.00 (0.91, 1.10)	46.65
Cohort			
Heilbrun et al, 1986		0.80 (0.33, 1.94)	1.14
Chyou et al, 1993		1.33 (0.96, 1.84)	4.17
Michaud et al, 1999		0.69 (0.40, 1.19)	2.39
Nagano et al, 2000		0.92 (0.60, 1.42)	3.15
Zeegers et al. 2001		0.53 (0.38, 0.73)	4.22
Kuranashi et al. 2009 Dec et el. 2011		1.17 (0.78, 1.75)	3.47
Ros et al, 2011 Subtatel (Leaverage = 07.00 ($z = 0.005$)		0.00 (0.07 4.47)	3.01
Subtotal (I-squared = 67.8% , p = 0.005)	~ _ P	0.88 (0.67, 1.17)	22.35
Overall (I-squared = 54.2%, p = 0.000)	\$	0.96 (0.86, 1.06)	100.00
NOTE: Weights are from random effects analy	sis		
404		0.00	

FIGURE 2 | The forest plot of tea consumption and the risk of bladder cancer.

TABLE 2 | Meta-analysis of tea consumption and bladder cancer risk.

Type of tea and subgroups	No. of studies	Test of assoc	ciation	<i>I</i> ² (%)	P-for heterogeneity		
		OR (95% CI)	P-value		P-for within group	P-for between group	
Tea	32	0.96 (0.86–1.06)	0.39	54.2	<0.001	_	
STUDY DESIGN							
НСС	12	0.98 (0.78–1.24)	0.90	63.2	0.002	0.45	
PCC	13	1.00 (0.91-1.10)	0.93	14.0	0.30		
Cohort	7	0.88 (0.67-1.17)	0.38	67.8	0.005		
SEX							
Male	14	1.02 (0.92–1.13)	0.75	1.3	0.44	0.51	
Female	13	0.93 (0.75-1.16)	0.51	22.8	0.21		
STUDY LOCATION		. ,					
America	17	0.99 (0.86–1.15)	0.94	61.9	<0.001	0.83	
Europe	9	0.87 (0.70–1.07)	0.17	46.8	0.06		
Asia	6	0.97 (0.78–1.21)	0.78	33.5	0.02		
ADJUSTMENT FOR AGE	-						
Yes	24	0.97 (0.84–1.10)	0.61	62.0	<0.001	0.75	
No	8	0.99 (0.90-1.09)	0.86	0	0.57		
ADJUSTMENT FOR SMOKING	-			-			
Yes	27	0.96 (0.86-1.08)	0.49	59.5	< 0.001	0.86	
No	5	0.97 (0.79–1.19)	0.79	0	0.49		
SMOKING STATUS	-			-			
Non-smokers	2	1.54 (0.60-3.94)	0.37	60.9	0.11	0.26	
Smokers	3	0.91 (0.61–1.36)	0.65	25.2	0.26	0.20	
Black tea	10	0.84 (0.70-1.01)	0.06	34.9	0.13	-	
STUDY DESIGN							
HCC	5	0.79 (0.58–1.08)	0.14	42.8	0.14	0.28	
PCC	2	0.80 (0.62-1.02)	0.07	0	0.51		
Cohort	3	1.06 (0.75–1.50)	0.73	9.3	0.33		
STUDY LOCATION							
America	4	0.83 (0.58-1.18)	0.30	63.5	0.04	0.42	
Europe	2	1.00 (0.56–1.80)	0.99	38.0	0.20		
Asia	4	0.83 (0.66-1.04)	0.10	0	0.45		
ADJUSTMENT FOR AGE							
Yes	7	0.83 (0.66-1.05)	0.12	44.9	0.09	0.60	
No	3	0.86 (0.58-1.27)	0.44	29.2	0.24		
ADJUSTMENT FOR SMOKING	ì						
Yes	9	0.85 (0.69–1.04)	0.11	41.8	0.09	0.40	
No	1	0.74 (0.38–1.44)	0.37	-	-		
Green tea	7	0.95 (0.73–1.24)	0.71	52.5	0.05	-	
STUDY DESIGN							
HCC	3	0.73 (0.53–1.00)	0.052	34.5	0.22	0.51	
PCC	1	1.04 (0.59–1.84)	0.89	-	-		
Cohort	3	1.20 (0.90–1.59)	0.22	0	0.86		
STUDY LOCATION							
America	3	0.90 (0.53–1.54)	0.71	75.9	0.02	0.79	
Asia	4	1.03 (0.53–1.54)	0.85	0	0.70		
Mate	2	2.17 (0.70–6.74)	0.18	75.0	0.05	-	
Oolong tea	1	3.00 (1.20-7.47)	0.02	_	-	_	

HCC, hospital-based case-control; PCC, population-based case-control; OR, odds ratio; Cl, confidence interval.

studies, no non-linearity association was observed ($P_{\text{non-linearity}} = 0.11$). The summary OR of bladder cancer for an increase of 1 cup/day of tea was 0.97 (95% CI 0.88–1.06, $P_{\text{linear}} = 0.47$).

For case-control studies, we found no evidence of a non-linearity association between tea consumption and bladder cancer risk $(P_{\text{non-linearity}} = 0.60)$. We then used the linear model among

case-control studies. The pooled OR of bladder cancer for an increase of 1 cup/day was 1.02 (95% CI 0.98–1.06, $P_{\text{linear}} = 0.27$).



FIGURE 3 | The dose-response analysis of tea consumption and the risk of bladder cancer. The black solid line and the black long dashed line represent the estimated RRs and corresponding 95% Cls for the non-linearity. The red solid line and the red short dashed line represent the estimated RRs and corresponding 95% Cls for the linearity.

Black Tea Consumption and Bladder Cancer

Black tea consumption was examined in 3 cohort studies (Heilbrun et al., 1986; Chvou et al., 1993; Nagano et al., 2000), 5 hospital-based case-control studies (Kunze et al., 1992; Wakai et al., 2004; Demirel et al., 2008; Hemelt et al., 2010; Wang J. et al., 2013), and 2 population-based case-control studies (Ohno et al., 1985; Nomura et al., 1991). No significant association was observed between black tea consumption and risk of bladder cancer (OR = 0.84, 95% CI 0.70-1.01) (Figure 4), with moderate between-study heterogeneity ($I^2 = 34.9\%$, $P_{\text{heterogeneity}} = 0.13$). For cohort studies, the combined OR was 1.06 (95% CI 0.75-1.50), with low between-study heterogeneity $(I^2 = 9.3\%, P_{\text{heterogeneity}} = 0.33)$ (Table 2). For hospital-based case-control studies, the pooled OR was 0.79 (95% CI 0.58-1.08), with low to moderate between-study heterogeneity ($I^2 =$ 42.8%, $P_{\text{heterogeneity}} = 0.14$). For population-based case-control studies, the combined OR was 0.80 (95% CI 0.62-1.02), with no between-study heterogeneity ($I^2 = 0.0\%$, $P_{\text{heterogeneity}} =$ 0.51).

Four case-control studies (Kunze et al., 1992; Wakai et al., 2004; Hemelt et al., 2010; Wang J. et al., 2013) were included for the dose-response meta-analysis of black tea consumption. The results had been shown in **Figure 5**.



FIGURE 4 | The forest plot of black tea consumption and the risk of bladder cancer.

There was no evidence of a non-linearity association between black tea consumption and bladder cancer risk ($P_{\text{non-linearity}} = 0.06$). A linear model was used among these studies. The poled OR of bladder cancer for an increase of 1 cup/day of black tea was 0.89 (95% CI 0.76–1.05, $P_{\text{linear}} = 0.18$).

OR (non-linearity) OR (linearity) OR

FIGURE 5 | The dose-response analysis of black tea consumption and the risk of bladder cancer. The black solid line and the black long dashed line represent the estimated RRs and corresponding 95% Cls for the non-linearity. The red solid line and the red short dashed line represent the estimated RRs and corresponding 95% Cls for the linearity.

Green Tea Consumption and Bladder Cancer

Green tea consumption was assessed in 3 cohort studies (Chyou et al., 1993; Nagano et al., 2000; Kurahashi et al., 2009), 3 hospitalbased case-control studies (Wakai et al., 2004; Hemelt et al., 2010; Wang J. et al., 2013), and one population-based case-control



FIGURE 7 | The dose-response analysis of green tea consumption and the risk of bladder cancer. The black solid line and the black long dashed line represent the estimated RRs and corresponding 95% Cls for the non-linearity. The red solid line and the red short dashed line represent the estimated RRs and corresponding 95% Cls for the linearity.

Study	%
ID	OR (95% CI) Weight
Cohort	
Chyou et al, 1993	1.34 (0.79, 2.27) 13.65
Nagano et al, 2000	1.07 (0.57, 2.03) 10.95
Kurahashi et al, 2009	1.17 (0.78, 1.75) 17.50
Subtotal (I-squared = 0.0%, p = 0.858)	1.20 (0.90, 1.59) 42.10
PCC	
Wilkens et al, 1996	1.04 (0.59, 1.84) 12.58
Subtotal (I-squared = .%, p = .)	1.04 (0.59, 1.84) 12.58
HCC	
Wakai et al, 2004	1.18 (0.49, 2.84) 7.03
Hemelt et al, 2010	0.83 (0.53, 1.29) 16.26
Wang et al, 2013	0.60 (0.45, 0.79) 22.03
Subtotal (I-squared = 34.5%, p = 0.217)	0.73 (0.53, 1.00) 45.32
Overall (I-squared = 52.5%, p = 0.049)	0.95 (0.73, 1.24) 100.00
NOTE: Weights are from random effects analysis	
.352 1	2.84

study (Wilkens et al., 1996). No significant association was observed between green tea consumption and bladder cancer risk (OR = 0.95, 95% CI 0.73–1.24) (**Figure 6**), with moderate heterogeneity ($I^2 = 52.5\%$, $P_{heterogeneity} = 0.05$). For cohort studies, the combined OR was 1.20 (95% CI 0.90–1.59), with no heterogeneity ($I^2 = 0.0\%$, $P_{heterogeneity} = 0.86$) (**Table 2**). For hospital-based case-control studies, the pooled OR was 0.73 (95% CI 0.53–1.00), with moderate between-study heterogeneity ($I^2 = 34.5\%$, $P_{heterogeneity} = 0.22$). For population-based case-control studies, the combined OR was 1.04 (95% CI 0.59–1.84).

Two cohort studies (Nagano et al., 2000; Kurahashi et al., 2009) and three case-control studies (Wakai et al., 2004; Hemelt et al., 2010; Wang J. et al., 2013) were included for the dose-response meta-analysis of green tea consumption. The results had

been shown in **Figure 7**. No evidence of non-linearity association was detected between green tea consumption and bladder cancer risk ($P_{non-linearity} = 0.92$). A linear model suggested that the summary OR of bladder cancer for an increase of 1 cup/day of green tea was 1.02 (95% CI 0.94–1.1, $P_{linear} = 0.66$).

Mate and Oolong Tea Consumption and Risk of Bladder Cancer

Mate consumption was investigated in 2 case-control studies (Bates et al., 2007; De Stefani et al., 2007). No significant association was observed between mate consumption and bladder cancer risk (OR = 2.17, 95% CI 0.70–6.74), with moderate to high between-study heterogeneity ($I^2 = 75.0\%$, $P_{heterogeneity} = 0.05$) (Table 2).



FIGURE 8 | Sensitivity analysis of tea consumption and risk of bladder cancer.

Oolong tea consumption was examined in only one study (Lu et al., 1999). An elevated risk was observed between oolong tea consumption and bladder cancer risk (OR = 3.00, 95% CI 1.20-7.47) (**Table 2**).

Subgroup and Meta-Regression Analyses

Results of subgroup analyses had been shown in Table 2. For tea consumption and risk of bladder cancer, subgroup analyses defined by study design, sex, study location, adjustment for age, adjustment for smoking, and smoking status did not show any substantial change in the summary OR, with no evidence of between-group heterogeneity by meta-regression analysis (Table 2). For black tea consumption and risk of bladder cancer, subgroup analyses defined by study design, study location, adjustment for age, and adjustment for smoking did not show any substantial change in the summary OR, with no evidence of between-group heterogeneity by meta-regression analysis (Table 2). For green tea consumption and risk of bladder cancer, subgroup analyses defined by study design and study location did not show any substantial change in the summary OR, with no evidence of between-group heterogeneity by meta-regression analysis (Table 2). Sensitivity analysis by removing four studies (Morgan and Jain, 1974; Howe et al., 1980; Zeegers et al., 2001a; Demirel et al., 2008) with crude ORs did not change the overall results of tea consumption among all studies (OR = 0.99, 95%CI 0.89–1.10), cohort studies (OR = 1.02, 95% CI 0.84–1.23), hospital-based case-control studies (OR = 1.01, 95% CI 0.78-1.32), and population-based case-control studies (OR = 1.00, 95% CI 0.90-1.11),; but the heterogeneity was reduced in cohort studies ($I^2 = 14.8\%$, P = 0.32 for heterogeneity) (Figure 8).

Publication Bias

No evidence of publication bias was detected in the tea (P = 0.43 for Egger's test; **Figure 9**), black tea (P = 0.76 for Egger's test; **Figure 10**), and green tea (P = 0.06 for Egger's test; **Figure 11**) consumption.

DISCUSSION

In present meta-analysis of seven prospective cohort studies that including 443 076 participants and 25 case-control studies that included 15 643 cases and 30 795 controls, we found that high level of tea intake was not significantly associated with bladder cancer risk. Specific analyses for black tea, green tea, and mate yielded similar results except for oolong tea. Doseresponse analyses showed that there was no non-linearity or linearity association between tea intake and bladder cancer risk.

There are two concerns to the previously published metaanalysis. For instance, dose-response relationship were left unaddressed and only reported data for the highest vs. lowest comparison in two studies (Zeegers et al., 2001b; Qin et al., 2012), and type of tea was not considered in one study (Zeegers et al., 2001b). Accordingly, we performed this study with refined methods, and we obtained results consistent with the previous ones. Tea is a mixture of a large number of bioactive compounds. Certain laboratory studies in multiple animal models have suggested that green tea extract or polyphenols could inhibit



FIGURE 9 | Funnel plot for tea consumption and risk of bladder cancer.







the activity of tumor at different organ site (Yang et al., 2009; Yang and Wang, 2011). Therefore, it is not clear from these observational studies whether the tea extractor or polyphenols are beneficial and randomized controlled trials or controlled feeding studies would help examine this problem.

Several limitations should be taken into consideration for our study. First, limitations of observational studies contain the problem of residual confounding that may also extend to meta-analysis of observational studies (Threapleton et al., 2013). The quality and usefulness of any meta-analytic study are dependent on the quality and comparability of information from the individual studies (Hennekens and Demets, 2009; Zhou et al., 2011). Second, our meta-analysis included studies performed in different countries since the 1970s, and some studies had certain weakness in study design that were without stratification of type of tea, and some studies did not adjust confounders. Most of the studies included in this meta-analysis adjusted for important confounding factors such as age, sex, and smoking in their analyses, but not all studies adjusted for other potentially important variables such as occupation or other dietary factors (e.g., alcohol, coffee, vegetables, and fruits). However, the meta-regression and subgroup analyses based on those factors did not observe any difference. Additionally, bladder cancer is a complicated and heterogeneous disease, which is noted for marked global variations in incidence and etiology. Therefore, the results of the present meta-analysis should be considered with certain caution because of potential confounding. Third, measurement error in dietary assessment is an inherent problem when evaluating relationships between diet and diseases (Threapleton et al., 2013). The potential for exposure misclassification of tea consumption was also a limitation. The interval between lowest and highest categories was different among included studies. Moreover, the unit of tea consumption was also much different among identified studies. The aforementioned two factors may contribute to the heterogeneity among studies in the aggregated analysis. Indeed, we detected moderate to high heterogeneity among included studies. Fourth, as we all know, green tea is popular in East Asians such as Chinese and Japanese population, and the sample size of Asians in this meta-analysis was relatively small. Therefore, the selection bias was inevitable and the relationship among different countries still remained unclear. Lastly, we did not search for unpublished studies; therefore, even though no publication bias was detected through funnel plot and Egger's

REFERENCES

- Bates, M. N., Hopenhayn, C., Rey, O. A., and Moore, L. E. (2007). Bladder cancer and mate consumption in Argentina: a case-control study. *Cancer Lett.* 246, 268–273. doi: 10.1016/j.canlet.2006.03.00
- Bianchi, G. D., Cerhan, J. R., Parker, A. S., Putnam, S. D., See, W. A., Lynch, C. F., et al. (2000). Tea consumption and risk of bladder and kidney cancers in a population-based case-control study. *Am. J. Epidemiol.* 151, 377–383. doi: 10.1093/oxfordjournals.aje. a010217
- Bruemmer, B., White, E., Vaughan, T. L., and Cheney, C. L. (1997). Fluid intake and the incidence of bladder cancer among middle-aged men and women in a three-county area of western Washington. *Nutr. Cancer* 29, 163–168. doi: 10.1080/01635589709514619

regression method, the publication bias might be inevitable. Lastly, the results of this meta-analysis showed that oolong tea consumption was associated with increased risk of bladder cancer. However, this finding was found only derived from one study (Lu et al., 1999). This intriguing finding wants further studies to investigate.

A major strength of this meta-analysis was the inclusion of observational studies from two main online database searches, identifying published studies from over two decades. The quality of the present meta-analysis was strengthened by assessing the quality of included studies and exploring dose-response relation not only reporting the comparisons of highest and lowest tea consumption. Different type of tea may have different influence. Therefore, we have evaluated the relationship between different type of tea and bladder cancer risk, which was an additional strength. Despite certain between-study heterogeneity was examined, the findings were generally consistent and the most of estimations were less than one. Therefore, drinking tea appears to be safe at habitual use.

In conclusion, this meta-analysis, consisting of 25 case-control studies and 7 cohort studies, had indicated that there was no significant association between tea consumption and the risk of bladder cancer. However, certain caution is need in interpreting the results from the present meta-analysis because of potential confounders and misclassification of tea consumption. Further studies with high quality and well-designed large scale are needed to provide more precise evidence.

AUTHOR CONTRIBUTIONS

XW, HW, and XZ conceived the study. HW and JK searched the databases and extracted the data. HW, SL, and TL analyzed the data. HW and XZ wrote the draft of the paper. XW reviewed the manuscript. All the authors approved the final manuscript.

ACKNOWLEDGMENTS

We thank Dr. Xiang-Yu Meng for language editing of this manuscript. This study was supported by The National Key Research and Development Program of China (2016YFC0106300).

- Chavan, S., Bray, F., Lortet-Tieulent, J., Goodman, M., and Jemal, A. (2014). International variations in bladder cancer incidence and mortality. *Eur. Urol.* 66, 59–73. doi: 10.1016/j.eururo.2013.10.001
- Chyou, P. H., Nomura, A. M., and Stemmermann, G. N. (1993). A prospective study of diet, smoking, and lower urinary tract cancer. Ann. Epidemiol. 3, 211–216. doi: 10.1016/1047-2797(93)90021-U
- Clavel, J., and Cordier, S. (1991). Coffee consumption and bladder cancer risk. *Int. J. Cancer* 47, 207–212. doi: 10.1002/ijc.2910470208
- Conde, V. R., Alves, M. G., Oliveira, P. F., and Silva, B. M. (2014). Tea (Camellia sinensis (L.)): a putative anticancer agent in bladder carcinoma? Anticancer Agents Med. Chem. 15, 26–36. doi: 10.2174/156652401466614120314314
- D'Avanzo, B., La Vecchia, C., Franceschi, S., Negri, E., Talamini, R., and Buttino, I. (1992). Coffee consumption and bladder cancer risk. *Eur. J. Cancer* 28A, 1480–1484. doi: 10.1016/0959-8049(92)90548-G

- De Stefani, E., Boffetta, P., Deneo-Pellegrini, H., Correa, P., Ronco, A. L., Brennan, P., et al. (2007). Non-alcoholic beverages and risk of bladder cancer in Uruguay. BMC Cancer 7:57. doi: 10.1186/1471-2407-7-57
- Demirel, F., Cakan, M., Yalcinkaya, F., Topcuoglu, M., and Altug, U. (2008). The association between personal habits and bladder cancer in Turkey. *Int. Urol. Nephrol.* 40, 643–647. doi: 10.1007/s11255-008-9331-1
- Egger, M., Davey Smith, G., Schneider, M., and Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. *BMJ* 315, 629–634. doi: 10.1136/bmj.315.7109.629
- Geoffroy-Perez, B., and Cordier, S. (2001). Fluid consumption and the risk of bladder cancer: results of a multicenter case-control study. *Int. J. Cancer* 93, 880–887. doi: 10.1002/ijc.1411
- Greenland, S. (1987). Quantitative methods in the review of epidemiologic literature. *Epidemiol. Rev.* 9, 1–30.
- Hartge, P., Hoover, R., West, D. W., and Lyon, J. L. (1983). Coffee drinking and risk of bladder cancer. J. Natl. Cancer Inst. 70, 1021–1026.
- Heilbrun, L. K., Nomura, A., and Stemmermann, G. N. (1986). Black tea consumption and cancer risk: a prospective study. Br. J. Cancer 54, 677–683. doi: 10.1038/bjc.1986.226
- Hemelt, M., Hu, Z., Zhong, Z., Xie, L. P., Wong, Y. C., Tam, P. C., et al. (2010). Fluid intake and the risk of bladder cancer: results from the South and East China case-control study on bladder cancer. *Int. J. Cancer* 127, 638–645. doi: 10.1002/ijc.25084
- Hennekens, C. H., and Demets, D. (2009). The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. *JAMA* 302, 2361–2362. doi: 10.1001/jama.2009.1756
- Higgins, J. P., and Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558. doi: 10.1002/sim.1186
- Howe, G. R., Burch, J. D., Miller, A. B., Cook, G. M., Esteve, J., Morrison, B., et al. (1980). Tobacco use, occupation, coffee, various nutrients, and bladder cancer. *J. Natl. Cancer Inst.* 64, 701–713.
- Jensen, O. M., Wahrendorf, J., Knudsen, J. B., and Sorensen, B. L. (1986). The Copenhagen case-control study of bladder cancer. II. Effect of coffee and other beverages. *Int. J. Cancer* 37, 651–657. doi: 10.1002/ijc.2910370503
- Jiang, X., Castelao, J. E., Groshen, S., Cortessis, V. K., Shibata, D. K., Conti, D. V., et al. (2008). Water intake and bladder cancer risk in Los Angeles County. *Int. J. Cancer* 123, 1649–1656. doi: 10.1002/ijc.23711
- Kunze, E., Chang-Claude, J., and Frentzel-Beyme, R. (1992). Life style and occupational risk factors for bladder cancer in Germany. A case-control study. *Cancer* 69, 1776–1790.
- Kurahashi, N., Inoue, M., Iwasaki, M., Sasazuki, S., and Tsugane, S. (2009). Coffee, green tea, and caffeine consumption and subsequent risk of bladder cancer in relation to smoking status: a prospective study in Japan. *Cancer Sci.* 100, 294–291. doi: 10.1111/j.1349-7006.2008.01027.x
- La Vecchia, C., Negri, E., Franceschi, S., D'Avanzo, B., and Boyle, P. (1992). Tea consumption and cancer risk. *Nutr. Cancer* 17, 27–31. doi: 10.1080/01635589209514170
- Leng, W. D., Zeng, X. T., Kwong, J. S. W., and Hua, X. P. (2015). Periodontal disease and risk of coronary heart disease: an updated metaanalysis of prospective cohort studies. *Int. J. Cardiol.* 201, 469–472. doi: 10.1016/j.ijcard.2015.07.087
- Lu, C. M., Lan, S. J., Lee, Y. H., Huang, J. K., Huang, C. H., and Hsieh, C. C. (1999). Tea consumption: fluid intake and bladder cancer risk in Southern Taiwan. Urology 54, 823–828. doi: 10.1016/S0090-4295(99)00281-2
- Michaud, D. S., Spiegelman, D., Clinton, S. K., Rimm, E. B., Curhan, G. C., Willett,
 W. C., et al. (1999). Fluid intake and the risk of bladder cancer in men. *N. Engl. J. Med.* 340, 1390–1397. doi: 10.1056/NEJM199905063401803
- Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 339:b2535. doi: 10.1136/bmj.b2535
- Morgan, R. W., and Jain, M. G. (1974). Bladder cancer: smoking, beverages and artificial sweeteners. *Can. Med. Assoc. J.* 111, 1067–1070.
- Nagano, J., Kono, S., Preston, D. L., Moriwaki, H., Sharp, G. B., Koyama, K., et al. (2000). Bladder-cancer incidence in relation to vegetable and fruit consumption: a prospective study of atomic-bomb survivors. *Int. J. Cancer* 86, 132–138. doi: 10.1002/(SICI)1097-0215(20000401)86:1<132::AID-IJC21>3.0.CO;2-M

- Nomura, A. M., Kolonel, L. N., Hankin, J. H., and Yoshizawa, C. N. (1991). Dietary factors in cancer of the lower urinary tract. *Int. J. Cancer* 48, 199–205. doi: 10.1002/ijc.291048020
- Ohno, Y., Aoki, K., Obata, K., and Morrison, A. S. (1985). Case-control study of urinary bladder cancer in metropolitan Nagoya. *Natl. Cancer Inst. Monogr.* 69, 229–234.
- Orsini, N., Li, R., Wolk, A., Khudyakov, P., and Spiegelman, D. (2012). Metaanalysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. *Am. J. Epidemiol.* 175, 66–73. doi: 10.1093/aje/kwr265
- Qin, J., Xie, B., Mao, Q., Kong, D., Lin, Y., and Zheng, X. (2012). Tea consumption and risk of bladder cancer: a meta-analysis. World J. Surg. Oncol. 10:172. doi: 10.1186/1477-7819-10-172
- Risch, H. A., Burch, J. D., Miller, A. B., Hill, G. B., Steele, R., and Howe, G. R. (1988). Dietary factors and the incidence of cancer of the urinary bladder. *Am. J. Epidemiol.* 127, 1179–1191.
- Ros, M. M., Bas Bueno-de-Mesquita, H. B., Buchner, F. L., Aben, K. K., Kampman, E., Egevad, L., et al. (2011). Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int. J. Cancer* 128, 2695–2708. doi: 10.1002/ijc.25592
- Sagara, Y., Miyata, Y., Nomata, K., Hayashi, T., and Kanetake, H. (2010). Green tea polyphenol suppresses tumor invasion and angiogenesis in N-butyl-(-4-hydroxybutyl) nitrosamine-induced bladder cancer. *Cancer Epidemiol.* 34, 350–354. doi: 10.1016/j.canep.2010.03.001
- Siegel, R. L., Miller, K. D., and Jemal, A. (2015). Cancer statistics, 2015. *CA Cancer J. Clin.* 65, 5–29. doi: 10.3322/caac.21254
- Slattery, M. L., West, D. W., and Robison, L. M. (1988). Fluid intake and bladder cancer in Utah. Int. J. Cancer 42, 17–22. doi: 10.1002/ijc.2910420105
- Stang, A. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur. J. Epidemiol.* 25, 603–605. doi: 10.1007/s10654-010-9491-z
- Threapleton, D. E., Greenwood, D. C., Evans, C. E., Cleghorn, C. L., Nykjaer, C., Woodhead, C., et al. (2013). Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. *BMJ* 347:f6879. doi: 10.1136/bmj.f6879
- Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108. doi: 10.3322/caac.21262
- Wakai, K., Hirose, K., Takezaki, T., Hamajima, N., Ogura, Y., Nakamura, S., et al. (2004). Foods and beverages in relation to urothelial cancer: case-control study in Japan. *Int. J. Urol.* 11, 11–19. doi: 10.1111/j.1442-2042.2004.00740.x
- Wang, J., Wu, X., Kamat, A., Barton Grossman, H., Dinney, C. P., and Lin, J. (2013). Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. Br. J. Cancer 108, 2372–2380. doi: 10.1038/bjc.2013.190
- Wang, X., Lin, Y. W., Wang, S., Wu, J., Mao, Q. Q., Zheng, X. Y., et al. (2013). A meta-analysis of tea consumption and the risk of bladder cancer. *Urol. Int.* 90, 10–16. doi: 10.1159/000342804
- Wilkens, L. R., Kadir, M. M., Kolonel, L. N., Nomura, A. M., and Hankin, J. H. (1996). Risk factors for lower urinary tract cancer: the role of total fluid consumption, nitrites and nitrosamines, and selected foods. *Cancer Epidemiol. Biomarkers Prev.* 5, 161–166.
- Woolcott, C. G., King, W. D., and Marrett, L. D. (2002). Coffee and tea consumption and cancers of the bladder, colon and rectum. *Eur. J. Cancer Prev.* 11, 137–145. doi: 10.1097/00008469-200204000-00005
- Wu, S., Li, F., Huang, X., Hua, Q., Huang, T., Liu, Z., et al. (2013). The association of tea consumption with bladder cancer risk: a meta-analysis. *Asian Pac. J. Clin. Nutr.* 22, 128–137. doi: 10.6133/apjcn.2013.22.1.15
- Xu, C., Zeng, X. T., Liu, T. Z., Zhang, C., Yang, Z. H., Li, S., et al. (2015). Fruits and vegetables intake and risk of bladder cancer: a PRISMA-compliant systematic review and dose-response meta-analysis of prospective cohort studies. *Medicine* 94:e759. doi: 10.1097/MD.00000000000759
- Yang, C. S., and Wang, H. (2011). Mechanistic issues concerning cancer prevention by tea catechins. *Mol. Nutr. Food Res.* 55, 819–831. doi: 10.1002/mnfr.201100036
- Yang, C. S., Wang, X., Lu, G., and Picinich, S. C. (2009). Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. *Nat. Rev. Cancer* 9, 429–439. doi: 10.1038/nrc2641

- Zeegers, M. P., Dorant, E., Goldbohm, R. A., and van den Brandt, P. A. (2001a). Are coffee, tea, and total fluid consumption associated with bladder cancer risk? Results from the Netherlands Cohort Study. *Cancer Causes Control* 12, 231–238. doi: 10.1023/A:1011245627593
- Zeegers, M. P., Tan, F. E., Goldbohm, R. A., and van den Brandt, P. A. (2001b). Are coffee and tea consumption associated with urinary tract cancer risk? A systematic review and meta-analysis. *Int. J. Epidemiol.* 30, 353–362. doi: 10. 1093/ije/30.2.353
- Zeng, X., Zhang, Y., Kwong, J. S., Zhang, C., Li, S., Sun, F., et al. (2015). The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. *J. Evid. Based Med.* 8, 2–10. doi: 10.1111/jebm. 12141
- Zeng, X. T., Leng, W. D., Zhang, C., Liu, J., Cao, S. Y., and Huang, W. (2015). Metaanalysis on the association between toothbrushing and head and neck cancer. *Oral Oncol.* 51, 446–451. doi: 10.1016/j.oraloncology.2015.02.095
- Zhang, Y. F., Xu, Q., Lu, J., Wang, P., Zhang, H. W., Zhou, L., et al. (2015). Tea consumption and the incidence of cancer: a systematic review and metaanalysis of prospective observational studies. *Eur. J. Cancer Prev.* 24, 353–362. doi: 10.1097/CEJ.00000000000094

Zhou, Y., Zhuang, W., Hu, W., Liu, G. J., Wu, T. X., and Wu, X. T. (2011). Consumption of large amounts of Allium vegetables reduces risk for gastric cancer in a meta-analysis. *Gastroenterology* 141, 80–89. doi: 10.1053/j.gastro.2011.03.057

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer Q.D. and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.

Copyright © 2017 Weng, Zeng, Li, Kwong, Liu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.